$RGPX
REGENEREX PHARMA, INC.

2023 Q4 Form 10-Q Financial Statement

#000147237523000142 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $2.400M
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $239.4K $2.786M $21.50K
YoY Change 722.57% 12855.37% 2.05%
Operating Profit -$239.4K -$2.786M -$21.50K
YoY Change 722.57% 12855.37% 2.05%
Interest Expense $20.22K $19.80K $16.61K
YoY Change 17.27% 19.23% -1.38%
% of Operating Profit
Other Income/Expense, Net -$24.59K -$15.53K $3.068K
YoY Change 21.15% -606.06% -130.02%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$264.0K -$2.801M -$18.44K
YoY Change 434.36% 15095.54% -45.38%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 277.9M shares 277.4M shares 277.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $7.856K $6.080K $629.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $1.423K $13.25K $2.500K
Receivables
Other Receivables
Total Short-Term Assets $9.279K $19.33K $3.129K
YoY Change 150.58% 517.77%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $842.9K $913.3K $5.632K
YoY Change 13437.79% 16116.51%
TOTAL ASSETS
Total Short-Term Assets $9.279K $19.33K $3.129K
Total Long-Term Assets $842.9K $913.3K $5.632K
Total Assets $852.1K $932.6K $8.761K
YoY Change 8482.35% 10545.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $78.95K $89.84K $66.19K
YoY Change 19.4% 35.73%
Accrued Expenses $83.23K $82.03K $104.3K
YoY Change -29.65% -21.32%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.560M $3.338M $780.4K
YoY Change 306.88% 327.71%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.560M $3.338M $780.4K
Total Long-Term Liabilities
Total Liabilities $4.728M $4.566M $1.036M
YoY Change 335.14% 340.72%
SHAREHOLDERS EQUITY
Retained Earnings -$5.323M -$5.059M -$1.976M
YoY Change 162.77% 155.98%
Common Stock $277.9K $277.9K $277.1K
YoY Change 0.3% 0.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.876M -$3.633M -$1.027M
YoY Change
Total Liabilities & Shareholders Equity $852.1K $932.6K $8.761K
YoY Change 8482.35% 10545.41%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$264.0K -$2.801M -$18.44K
YoY Change 434.36% 15095.54% -45.38%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Entity Central Index Key
EntityCentralIndexKey
0001357878
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
CY2023Q1 us-gaap Notes Payable
NotesPayable
usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
usd
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
usd
RGPX Noncash Or Part Noncash Acquisition Of Intangible Assets Excluding Goodwill
NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53230
dei Entity Registrant Name
EntityRegistrantName
REGENEREX PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0479983
dei Entity Address Address Line1
EntityAddressAddressLine1
5348 Vegas Drive #177
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89108
dei City Area Code
CityAreaCode
(877)
dei Local Phone Number
LocalPhoneNumber
761-7479
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
277915910 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6080 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1135 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
13250 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
19330 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1135 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
27834 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
26397 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2766 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4203 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
735 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
197 usd
CY2023Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
6962 usd
CY2023Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
1201 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
903586 usd
CY2023Q3 us-gaap Assets
Assets
932644 usd
CY2023Q1 us-gaap Assets
Assets
6539 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
89840 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
75145 usd
CY2023Q3 RGPX Related Party Advances
RelatedPartyAdvances
2637 usd
CY2023Q1 RGPX Related Party Advances
RelatedPartyAdvances
131887 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
318077 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
221192 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
82034 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
125787 usd
CY2023Q3 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
282786 usd
CY2023Q1 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
222771 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
2400000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
162295 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3337669 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
776782 usd
CY2023Q3 RGPX Notes Payable Shareholder
NotesPayableShareholder
275905 usd
CY2023Q1 RGPX Notes Payable Shareholder
NotesPayableShareholder
314704 usd
CY2023Q3 RGPX Notes Payable Related Parties
NotesPayableRelatedParties
4000 usd
CY2023Q1 RGPX Notes Payable Related Parties
NotesPayableRelatedParties
38000 usd
CY2023Q3 us-gaap Notes Payable
NotesPayable
184232 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
764171 usd
CY2023Q3 us-gaap Liabilities
Liabilities
4565977 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1129486 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
277915910 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
277915910 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
277112660 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
277112660 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
277916 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
277113 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1147798 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
671963 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5059047 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2072023 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3633333 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1122947 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
932644 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6539 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
385923 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21504 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
546097 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38789 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2400000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2400000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2785923 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
21504 usd
us-gaap Operating Expenses
OperatingExpenses
2946097 usd
us-gaap Operating Expenses
OperatingExpenses
38789 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2785923 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21504 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2946097 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-38789 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
19801 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
16607 usd
us-gaap Interest Expense
InterestExpense
38307 usd
us-gaap Interest Expense
InterestExpense
32125 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4275 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
19675 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2620 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
29274 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15526 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3068 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-40927 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2851 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2801449 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18436 usd
us-gaap Net Income Loss
NetIncomeLoss
-2987024 usd
us-gaap Net Income Loss
NetIncomeLoss
-41640 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277516358 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277112660 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277337306 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277112660 shares
us-gaap Net Income Loss
NetIncomeLoss
-2987024 usd
us-gaap Net Income Loss
NetIncomeLoss
-41640 usd
us-gaap Depreciation
Depreciation
1975 usd
us-gaap Depreciation
Depreciation
1794 usd
us-gaap Share Based Compensation
ShareBasedCompensation
133388 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2400000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
22880 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2620 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
29274 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-13250 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2756 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
146125 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
21852 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-293286 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44512 usd
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
6299 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6299 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2437 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
7600 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2843 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
34901 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
343250 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
304530 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42501 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4945 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2011 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1135 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2640 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6080 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
629 usd
RGPX Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
78194 usd
RGPX Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
4015 usd
RGPX Operating Leases Rou Asset And Liabilities
OperatingLeasesRouAssetAndLiabilities
953535 usd
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
150000 usd
RGPX Noncash Or Part Noncash Acquisition Of Intangible Assets Excluding Goodwill
NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill
2400000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-985617 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23204 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1008821 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1008821 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18436 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1027257 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1122947 usd
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
190000 shares
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
190000 shares
CY2023Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
30000 shares
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
34554 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-185575 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1083968 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1083968 usd
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
153250 shares
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
153250 usd
CY2023Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
430000 shares
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
98834 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2801449 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3633333 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin: 0px; font-size: 10pt"><b>NOTE 1 – NATURE OF OPERATIONS</b></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.</p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15<sup>th</sup> of the following month, for a period of 60 months.  The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter the wound treatment market in the U.S.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties</i><span style="font-size: 10pt"> </span></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows.</p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has a lack of revenue history and has had a limited history of operations.  No revenue has historically been derived from the assets purchased.  Regenerex can give no assurance of success or profitability to the Company’s investors.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The wound care healing space is well suited for Home Care service providers that are funded by the US Government. Strategic planning and development will be performed internally by the Company.<span style="font-size: 10pt"> </span></p> <p style="margin: 0px; font-size: 10pt"> </p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-18
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10000000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
723 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
723 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1437 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1794 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3633333 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2306250 shares
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2023Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P3Y
us-gaap Property Plant And Equipment Preproduction Design And Development Costs
PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts
<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Furniture and Computer Equipment</i></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Furniture and computer equipment are stated at cost, less accumulated depreciation.  Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years.  Depreciation expense for the three and six months ended September 30, 2023 and 2022 was $422 and $0 and $538 and $0, respectively.  Significant betterments are capitalized while purchases under $500 are expensed as incurred.</p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span class="adv_highlightanchor adv_pagination" id="page_7"></span></p> <p style="margin: 0; font-size: 10pt"></p> <p style="margin: 0px; font-size: 10pt"> </p>
CY2023Q2 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
422 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
0 usd
CY2022Q2 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
538 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
0 usd
CY2023Q3 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.10 pure
us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.10 pure
CY2023Q3 RGPX Related Party Advances
RelatedPartyAdvances
2637 usd
CY2023Q1 RGPX Related Party Advances
RelatedPartyAdvances
131887 usd
CY2023Q3 RGPX Notes Payable Related Parties
NotesPayableRelatedParties
4000 usd
CY2023Q1 RGPX Notes Payable Related Parties
NotesPayableRelatedParties
38000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
1630 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
129 usd
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
10 pure
CY2021Q4 us-gaap Business Combination Contingent Consideration Arrangements Description
BusinessCombinationContingentConsiderationArrangementsDescription
and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10000000 usd
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028.  Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company’s procedures.  We expect to launch production during the Company’s third or fourth quarter and will notify the FDA to come into the plant for the inspection at that time.  The Company is able to start production while the plant waits for the FDA Inspection.  Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of  each June from June 2023 to June 2027.
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0519 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0554 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.800 pure
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.18
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
343250 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
343250 usd
us-gaap Temporary Equity Contract Terms
TemporaryEquityContractTerms
Five warrants were issued for each share purchased, for a total of 1,716,250 warrants.  The warrants are exercisable at twenty ($0.20) cents and expire from April 2025 through September 2025.
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2306250 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
2216238 shares

Files In Submission

Name View Source Status
0001472375-23-000142-index-headers.html Edgar Link pending
0001472375-23-000142-index.html Edgar Link pending
0001472375-23-000142.txt Edgar Link pending
0001472375-23-000142-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ixform10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
ixform10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regenerexlogo.gif Edgar Link pending
report.css Edgar Link pending
rgpx-20230930.xsd Edgar Link pending
Show.js Edgar Link pending
rgpx-20230930_lab.xml Edgar Link unprocessable
rgpx-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
rgpx-20230930_cal.xml Edgar Link unprocessable
rgpx-20230930_pre.xml Edgar Link unprocessable